Equity Research Electromedical & Electrotherapeutic Apparatus

Should You Buy ENDRA Life Sciences Inc. Stock in 2026?

By CirclFi Research Team · · 6/13 models active

According to the CirclFi Deep Alpha Valuation Engine, ENDRA Life Sciences Inc. (NDRA) presents a moderate quality profile with a QOC score of 3.8/10. Trading at $5.61, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.

The short answer: 4 of 6 CirclFi valuation models project upside for ENDRA Life Sciences Inc. (NDRA) at $5.61 — the model consensus leans bullish, with a Quality Score of 3.8/10 and Value-Trap risk of 39/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 4 of 6 models see upside — majority bullish
  • Quality Score: 3.8/10 — Weak — below-average fundamentals
  • Value Trap Risk: 39/100 — Low — manageable risk
  • Fair Value Range: $1.30 – $10.04 (674% spread)

Bullish Models

4 / 6

Bearish Models

2 / 6

Quality Score

3.8 /10

Weak — below-average fundamentals

Value Trap Risk

39 /100
Low

Low — manageable risk

Model Consensus

6 /13
Active Models

Avg. confidence: 24%

Investment Thesis

The Bull Case

Target: $10.04 (+79.0% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model targets a fair value of $10.04 (+79.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $1.30 (-76.9%)

  • According to the CirclFi Quality of Company (QOC) framework, ENDRA Life Sciences Inc.'s rating of 3.8/10 indicates below-average quality, raising questions about sustainable earnings levels.
  • According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $1.30 (-76.9%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +155.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

Peer Benchmarking

INMD InMode Ltd.
9.9
ELMD Electromed, Inc.
9.4
LIVN LivaNova PLC
9.1
CNMD CONMED Corporation
8.9
ITGR Integer Holdings Cor
8.3

Valuation Divergence

Spread

674%

Fair Value Range

$1.30 – $10.04

A 674% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Dynamic NAV

$10.04 (+79.0%)

Most Bearish

Bayesian DCF

$1.30 (-76.9%)

Key Risk Factors

Weak Fundamentals

QOC 3.8/10 signals below-average quality.

Model Disagreement

674% spread signals high variance in projections.

Macro/Sector Risk

Electromedical & Electrotherapeutic Apparatus headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View NDRA Data Page →

The Bottom Line

Our models don't have a clear verdict on ENDRA Life Sciences Inc.. At $5.61 vs. $5.64 composite fair value, the average upside of +0.5% masks significant model disagreement (+155.9% spread). With quality at 3.8/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.

These are quantitative model outputs, not investment recommendations. ENDRA Life Sciences Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy NDRA stock right now?

Based on CirclFi's multi-model analysis, 4 of 6 models see upside for NDRA at $5.61. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 3.8/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in ENDRA Life Sciences Inc.?

Key risks include: a below-average Quality Score of 3.8/10, indicating fundamental weakness; limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (674% spread), signaling high uncertainty; general market and sector-specific risks affecting Electromedical & Electrotherapeutic Apparatus companies. Always diversify and consult a financial advisor.

How does NDRA compare to its competitors?

Among Electromedical & Electrotherapeutic Apparatus peers, NDRA holds a Quality Score of 3.8/10. Comparable companies include INMD (QOC 9.9), ELMD (QOC 9.4), LIVN (QOC 9.1). The relative ranking helps investors identify whether NDRA offers better fundamental quality than alternatives in the same sector.

Is NDRA a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NDRA's Quality Score of 3.8/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy NDRA at?

CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $1.30 to $10.04. At $5.61, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for NDRA.

View NDRA Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →